Lynda Charters

They report a case of endophthalmitis and undertook a literature review to identify previous infections with this pathogen.

Cost among other factors may deter patients from screening, especially in rural and low-resource settings.

LHON, a genetic disease that affects the retinal ganglion cells, results in severe bilateral sequential vision loss.

The rationale was that commercial mydriatics administered during retinopathy of prematurity (ROP) screening have been associated with cardiorespiratory and gastrointestinal adverse events.

A single lot (Lot 10101) of Systane Lubricant Eye Drops Ultra PF, Single Vials On-the-Go, 25 count, is being voluntarily recalled by Alcon Laboratories due to the detection of fungal material in a consumer-reported vial.

The researchers conducted a retrospective study to assess serum inflammatory biomarkers in patients with different subtypes of diabetic macular edema (DME).

Recognition may translate into policy changes and behavioral improvement.

Researchers described the presence of multiple bilateral serous retinal detachments (SRDs) found in 3 women after they used hair dyes.

It is noteworthy that patients with mild TBI often report visual issues despite normal results of visual acuity measurements and fundus examinations.

The authors searched PubMed, Scopus, MEDLINE, ScienceDirect, and ClinicalTrials.gov, and selected studies based on reports with an association between RVO and heart attack risk.

The investigators conducted a randomized controlled trial of 60 patients who underwent monitored anesthesia care sedation for oculoplastic procedures from August 2018 to November 2020.

Research needed to establish best diagnostic and management strategies for increasingly common condition.

In a recent Modern Retina case-based discussion, Ferhina S. Ali, MD, MPH, discussed how to effectively manage geographic atrophy (GA).

A case report demonstrates independent effect of GLP-1 receptor agonist.

Srinivas R. Sadda, MD, described the advantages and disadvantages of the various imaging technologies used to evaluate GA at the AAO 2024 conference.

Katherine Talcott, MD, discussed other potential therapies and their mechanisms of action being evaluated in clinical trials at the OSN New York 2024 conference.

Dr. Mammo discussed this evolution and how to choose patients who would best benefit from GA therapy.

They went on to explain that biomarkers such as VD in the superior capillary plexus (SCP), deep capillary plexus (DCP), and foveal avascular zone (FAZ) are promising because previous studies have reported changes in vascular density in the brain and retina in AD.